Results 171 to 180 of about 146,560 (338)

Health‐related quality of life in youth with chronic gastrointestinal disease following a biofeedback enhanced cognitive behavioral therapy intervention: A randomized controlled trial

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Pediatric patients with chronic gastrointestinal (GI) conditions including inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS) on average endorse lower health related quality of life (HRQOL) than their healthy counterparts.
S. Taylor Younginer, Adrianna Westbrook, Jessica Buzenski, Chelly Dykes, Subra Kugathasan, Clair Talmadge, Bonney Reed   +6 more
wiley   +1 more source

Understanding life experiences of people affected by Crohn's disease in Spain. A phenomenological approach [PDF]

, 2017
Sofía García‐Sanjuán, Manuel Lillo‐Crespo, Miguel Richart‐Martínez, Ángela Sanjuán Quiles   +3 more
openalex   +1 more source

Comparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulation

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Serena Yun‐Chen Tsai, Ashwin N. Ananthakrishnan, Harland S. Winter, Kevin Sheng‐Kai Ma   +3 more
wiley   +1 more source

Real‐world data on STRIDE‐II treatment targets in a pediatric cohort with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives STRIDE (selecting therapeutic targets in inflammatory bowel disease) established evidence‐based targets for treat‐to‐target strategies in IBD. STRIDE‐II designates clinical remission, C‐reactive protein (CRP) normalization, and fecal calprotectin (FC) reduction as short‐ to intermediate‐term targets, and mucosal healing as a long ...
Marie‐Luise Frank, Thu Giang Le Thi, Ina Schacker, Lena Bragagna, Milena Geist, Simon Buehler, Victoria Riedl, Sibylle Koletzko, Tobias Schwerd, Hannes Hoelz   +9 more
wiley   +1 more source

Health Technology Assessment of Infliximab: A Rapid Review of Type 2 Studies

مجله دانشکده پزشکی اصفهان, 2012
Background: Infliximab has been used for treatment of patients with Crohn's disease whose symptoms or developed fistula could not be eliminated by standard treatments.
Mohamadreza Mobinizadeh, Alireza Oliyaeemanesh, Sheila Doaee, Mina Nejati, Parisa Aboee, Mahdi Azadbakht, Mahboubeh Valadkhani6   +6 more
doaj  

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation [PDF]

Dingsheng Liu, Banghua Zhong, Lili Guo
openalex   +1 more source

Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease [PDF]

, 2012
P. Álvarez, María Chaparro, Andrés Pérez-Casas, Aurora Muriel-Herrero, Javier P. Gisbert   +4 more
openalex   +1 more source

A Rare Cause of Myopathy and Paralysis in Crohn's Disease

, 2023
Taylan Metin
openalex   +1 more source

Crohn's Disease [PDF]

Postgraduate Medical Journal, 1953
openaire   +2 more sources

The attitudes and beliefs of Australasian pediatric gastroenterologists and dietitians toward the Crohn's disease exclusion diet

JPGN Reports, EarlyView.
Abstract Objectives Nutritional therapy plays a crucial role in managing pediatric Crohn's disease (CD). Exclusive enteral nutrition (EEN) is the primary induction therapy, achieving high remission and mucosal healing rates. However, its restrictive nature poses psychological and practical challenges.
Stephanie C. Brown, Emma Landorf, Nir Fireman, Anna Richards, Andrew S. Day   +4 more
wiley   +1 more source